Ypsomed Holding AG represents a set of core values and a strong corporate philosophy. The company is dedicated to innovation, quality, and patient-centric solutions in the field of medical devices and self-medication systems. Ypsomed prioritizes customer satisfaction through the development of user-friendly and technologically advanced products. With a focus on sustainability, Ypsomed aims to reduce environmental impact throughout its operations. The company fosters a culture of close collaboration, teamwork, and integrity, promoting transparency and trust among its employees and stakeholders. Ypsomed Holding AG's commitment to excellence, social responsibility, and continuous improvement underpins its position as a leading player in the healthcare industry.

Ypsomed Holding AG is primarily present in various countries and regions. This prominent company has a global presence, with operations spanning across Europe, Asia, and the Americas. In Europe, Ypsomed Holding AG has a significant presence in countries like Switzerland, Germany, France, Italy, and the United Kingdom. Additionally, it has established a strong foothold in Asian markets, including Japan, China, India, and South Korea. Furthermore, Ypsomed Holding AG also maintains a presence in the Americas, particularly in the United States and Canada. With its extensive international reach, Ypsomed Holding AG is renowned for its wide geographical distribution and successful market penetration.

Ypsomed Holding AG, a reputable medical technology company, has achieved numerous significant milestones throughout its history. Some notable achievements include the development and launch of its flagship product, the mylife™ Diabetescare range, which revolutionized insulin pump therapy. Ypsomed also successfully partnered with leading pharmaceutical companies to develop innovative drug delivery systems. Furthermore, the company received regulatory approvals from various health authorities worldwide, expanding its market reach. Ypsomed Holding AG's continuous commitment to research and innovation has led to the introduction of cutting-edge medical devices that empower patients and healthcare professionals alike.

Ypsomed Holding AG is a Swiss company specializing in the development and manufacture of innovative injection and infusion systems. Established in 2003, Ypsomed has a rich history of more than 30 years, as it originated from Disetronic, a company established in 1984. Ypsomed focuses on providing self-care solutions for diabetes, which include self-injection pens, autoinjectors, and infusion systems. The company has a strong commitment to enhancing the quality of life for patients and continuously strives to develop user-friendly and reliable medical devices. Ypsomed Holding AG has a global presence and collaborates with various partners to deliver cutting-edge healthcare solutions worldwide.

The main competitors of Ypsomed Holding AG in the market include Johnson & Johnson, Medtronic, Becton Dickinson, and Roche Holding AG.

Ypsomed Holding AG is primarily active in the healthcare industry.

The business model of Ypsomed Holding AG revolves around the production and supply of innovative and high-quality injection and infusion systems for self-medication. Ypsomed specializes in developing and manufacturing pen needles, autoinjectors, and infusion systems for the treatment of diabetes, Parkinson's disease, and other medical conditions. The company's business model focuses on meeting the needs of patients, healthcare professionals, and pharmaceutical companies by providing user-friendly and reliable self-medication solutions. Ypsomed Holding AG has built a strong reputation in the healthcare industry for its commitment to innovation, quality, and patient-centric approach.

The Ypsomed Holding P/E ratio is 48.35.

The Ypsomed Holding P/S ratio is 5.65.

The Quality Investing for Ypsomed Holding is 7/10.

The Ypsomed Holding revenue is 748.87 M CHF.

The Ypsomed Holding profit is 87.5 M CHF.

The company Ypsomed Holding AG is a leading company in the manufacture and distribution of injection and infusion systems. Ypsomed's business model is based on the production and sale of products for self-medication and medication administration. The main focus is on the easy handling of the products and the resulting improvement in patients' quality of life. Ypsomed is divided into several divisions that focus on different products and areas of the company. The main divisions are: 1. Diabetes Care Ypsomed is a major manufacturer of diabetes treatment products. In this area, the company offers both insulin pens and insulin pumps. The most well-known products include the insulin pen product family mylife™, the pod-based insulin pump family YpsoPump®, and the web-based data management tool Ypsomed Smart Services™. 2. Pharma Supply In the Pharma Supply division, Ypsomed offers individual solutions for medication administration. This includes pens for other indications, such as growth hormone deficiency or psoriatic arthritis, as well as injection and infusion solutions. 3. Contract Manufacturing In addition, the company offers contract manufacturing of injection and infusion systems for third-party customers. Ypsomed works closely with pharmaceutical companies to produce individual solutions for their products. Ypsomed's business model is based on an integrated approach, covering the entire value chain from product development to distribution and service. This means that Ypsomed is able to quickly bring innovative products to market and offer generic products at competitive prices through production. Through distribution via wholesale, distributors, and direct sales, Ypsomed reaches a wide range of customers and patients worldwide. A key element of Ypsomed's business model is close cooperation with healthcare providers and customers who directly supply the products to end consumers. This ensures that market needs are identified early and implementation strategies are developed. In summary, Ypsomed's business model offers patients, pharmaceutical companies, and healthcare providers a wide range of injection and infusion systems for safe and easy use in everyday life. Ypsomed focuses on quality, innovation, and partnerships. Ypsomed aims to maintain its leadership in self-medication innovation and be an important partner for pharmaceutical companies and healthcare institutions worldwide. With this approach, Ypsomed aims for further growth and sustainable development.

Ypsomed Holding pays a dividend of 0.3 CHF distributed over payouts per year.

The dividend cannot currently be calculated for Ypsomed Holding or the company does not pay out a dividend.

The ISIN of Ypsomed Holding is CH0019396990.

The WKN of Ypsomed Holding is A0B8VP.

The ticker of Ypsomed Holding is YPSN.SW.

Over the past 12 months, Ypsomed Holding paid a dividend of 1 CHF . This corresponds to a dividend yield of about 0.32 %. For the coming 12 months, Ypsomed Holding is expected to pay a dividend of 1.13 CHF.

The current dividend yield of Ypsomed Holding is 0.32 %.

Ypsomed Holding pays a quarterly dividend. This is distributed in the months of August, August, August, August.

Ypsomed Holding paid dividends every year for the past 0 years.

For the upcoming 12 months, dividends amounting to 1.13 CHF are expected. This corresponds to a dividend yield of 0.36 %.

Ypsomed Holding is assigned to the 'Health' sector.

To receive the latest dividend of Ypsomed Holding from 7/8/2025 amounting to 1.1 CHF, you needed to have the stock in your portfolio before the ex-date on 7/4/2025.

The last dividend was paid out on 7/8/2025.

In the year 2024, Ypsomed Holding distributed 0.65 CHF as dividends.

The dividends of Ypsomed Holding are distributed in CHF.